Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Scleroderma: it has been a long hard journey.

P J Roberts-Thomson1, J G Walker

  • 1Department of Immunology, Allergy and Arthritis, Flinders Medical Centre, Adelaide, South Australia, Australia. peter.roberts-thomson@flinders.edu.au

Internal Medicine Journal
|July 27, 2006
PubMed
Summary

Understanding scleroderma, or systemic sclerosis, has advanced slowly, hindering effective treatments. Recent developments offer cautious optimism for new therapies and improved patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The impact of gastroesophageal reflux disease and its treatment on interstitial lung disease outcomes.

Arthritis research & therapy·2024
Same author

Evidence of chromosomal damage in scleroderma.

Pathology·2021
Same author

Anti-Ro52/TRIM21 is independently associated with pulmonary arterial hypertension and mortality in a cohort of systemic sclerosis patients.

Scandinavian journal of rheumatology·2021
Same author

Is contact between men who have sex with men and non-governmental organizations providing harm reduction associated with improved HIV outcomes?

HIV medicine·2020
Same author

Cancer risk assessment tools in primary care: a systematic review of randomized controlled trials.

Annals of family medicine·2015
Same author

Cost savings with a new screening algorithm for pulmonary arterial hypertension in systemic sclerosis.

Internal medicine journal·2015

Area of Science:

  • Rheumatology
  • Immunology
  • Dermatology

Background:

  • Scleroderma (systemic sclerosis) aetiopathogenesis understanding has historically lagged, impeding targeted therapies.
  • This review covers the historical context of scleroderma research, including Australian contributions.
  • Recent advancements in understanding disease mechanisms are highlighted.

Discussion:

  • Slow progress in scleroderma pathogenesis has limited disease-modifying treatments.
  • Emerging research sheds light on key pathogenic pathways.
  • New therapeutic strategies are being explored based on recent findings.

Key Insights:

  • Despite historical challenges, recent pathogenic developments offer new insights.
  • Novel therapeutic approaches show promise for scleroderma management.

Related Experiment Videos

  • A deeper understanding of disease mechanisms is crucial for treatment innovation.

    • Outlook:

    • Cautious optimism is warranted for scleroderma patients due to emerging therapies.
    • Future research directions focus on translating pathogenic understanding into clinical practice.
    • Continued investigation into scleroderma aetiopathogenesis may accelerate the development of specific treatments.